Crinetics Pharmaceuticals' Palsonify Gains Momentum in Acromegaly Treatment with Positive Endorsement and Promising Pipeline Expansion

Crinetics Pharmaceuticals' Palsonify received positive feedback from endocrinologists at the ENDO conference for its efficacy, durability, and convenient once-daily dosing. The drug is a potential new standard of care for acromegaly treatment, offering advantages over existing treatments. Palsonify was well tolerated in open-label extension data from the PATHFNDR studies, further supporting its potential for FDA approval. Additionally, Crinetics' pipeline includes CRN12755, a candidate for Graves' disease and thyroid eye disease. Analysts maintain a bullish stance on CRNX stock, with a Buy rating and a $71.00 price target.

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) presented compelling data on its lead drug candidate, Palsonify (paltusotine), at the ENDO 2025 conference, demonstrating its potential to revolutionize acromegaly treatment. The drug received positive feedback from endocrinologists for its efficacy, durability, and convenient once-daily dosing regimen. This positive reception reinforces Crinetics' position as a leader in innovative endocrinology treatments.

Palsonify was well-tolerated and showed sustained control of IGF-1 levels in open-label extension data from the PATHFNDR-1 and PATHFNDR-2 studies [1]. The drug's once-daily dosing regimen offers a significant advantage over existing treatments, allowing patients to take it at bedtime without concerns about fasting and food effects associated with twice-daily oral somatostatin receptor ligands (SRLs). Endocrinologists consulted by H.C. Wainwright and other analysts expect a majority of acromegaly patients to switch to Palsonify, highlighting its potential to become the new standard of care [2].

Crinetics' pipeline also includes CRN12755, a candidate for Graves' disease and thyroid eye disease, further bolstering its drug discovery capabilities. The company's strong progress with multiple indications and upcoming PDUFA dates for Palsonify have analysts bullish on CRNX stock. H.C. Wainwright reiterated its Buy rating with a $81.00 price target, while Jones Trading maintained a Buy rating with a $71.00 price target, highlighting the sustained biochemical control observed in the PATHFNDR studies [2].

Crinetics Pharmaceuticals' continued focus on innovation and its robust pipeline position it well for future growth. Investors should closely monitor the company's upcoming financial results and regulatory milestones to gauge its progress and potential impact on the stock price.

References:
[1] https://stockanalysis.com/stocks/crnx/
[2] https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-buy-rating-on-crinetics-stock-at-81-price-target-93CH-4143703